ATLANTA, GA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (the “Company”) (NYSE American: RHE) (NYSE American: RHE-PA) (OTCQB Venture: RHEPB), a self-managed healthcare real estate investment company that invests primarily in real estate purposed for senior living and long-term care, announced today that its 12.5% Series B Cumulative Redeemable Preferred Shares (the “Series B Preferred Stock”) commenced trading on the OTCQB Venture Market, operated by the OTC Markets Group, Inc., under the symbol “RHEPB”.
The Company’s Common Stock and Series A Redeemable Preferred Shares will continue to trade on the NYSE American LLC under the symbols “RHE” and “RHE-PA,” respectively. The Company will continue to file its required periodic reports and other filings with the Securities and Exchange Commission.
About Regional Health Properties
Regional Health Properties, Inc., a Georgia corporation, is a self-managed healthcare real estate investment company that invests primarily in real estate purposed for senior living and long-term care. For more information, visit www.regionalhealthproperties.com.
| Company Contact |
| Brent Morrison, CFA |
| Chief Executive Officer & President |
| Regional Health Properties, Inc. |
| Tel (678) 368-4402 |
| This email address is being protected from spambots. You need JavaScript enabled to view it. |

| Last Trade: | US$2.77 |
| Daily Volume: | 0 |
| Market Cap: | US$5.220M |

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load